Kalytera Therapeutics Inc., a Canada based specialty pharmaceutical company has announced the initiation of a program to develop an oral analgesic, which is potent and non-psychotropic for safely treating intractable pain.
The company secures an exclusive, worldwide license for this product that it has acquired from an Israel-based pharmaceutical company, Beetlebung Pharma Ltd. It has also registered patents in the United States.
This novel cannabinoid compound is combined with an already approved generic, anti-inflammatory and the non-steroidal drug called naproxen to develop a next-generation line of pain treatment. Both cannabidiol and naproxen have compatible activity mode along with superior safety profile and thus, work in synergistic effect to treat pains. The compound being water soluble further broadens its scope of treating the pain in in-patient settings such as childbirth, surgeries and post-operative pains.
Many research studies conducted on cannabidiols support the clinical benefits of the compound in treating pains. As published in the Journal of Neuroimmune Pharmacology, a systematic review of a randomized controlled trial on cannabinoids revealed its remarkable pain relieving potentials along with high tolerance by the human body.
The market for cannabinoid and naproxen conjugate is highly untapped, thus offers great commercialization scope to the company. The current pain treatment market comprises of Non-Steroidal Anti-Inflammatory (NSAIDs) drugs that treat mild to moderate pain. However, this novel drug would be catering to the moderate to severe pain segment without causing respiratory suppression and dependence like opioids. As per the reports of Transparency Market Research in 2016, the global therapeutic market for pain management is speculated to reach $83 billion by 2024.